S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms
    Meeting Abstract

    Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso, G. T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649
    Meeting Abstract

    Möhler, M.; Shitara, K.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; Liu, T.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical phenotypes of CAR-T-cell related hematotoxicity in relapsed/refractory large B-cell lymphoma
    Meeting Abstract

    Rejeski, K.; Sesques, P.; Berger, C.; Jentzsch, L.; Mougiakakos, D.; Frölich, L.; Bücklein, V.; Blumenberg, V.; Schmidt, C.; Jallades, L.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
    Meeting Abstract

    Gautschi, O.; Subbiah, V.; Konda, B.; Bauer, T.; McCoach, C.; Falchook, G.; Takeda, M.; Patel, J.; Weiss, J.; Peled, N.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer
    Meeting Abstract

    Leyvraz, S.; Hong, D. S.; Shen, L.; van Tilburg, C. M.; Tan, D. S. W.; Kummar, S.; Lin, J. J.; Doz, F.; McDermott, R.; Albert, C. M.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Meeting Abstract

    Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Clinical benefit with ripretinib as ≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS study
    Meeting Abstract

    Bauer, S.; Heinrich, M.; George, S.; Zalcberg, J. R.; Gelderblom, H.; Schöffski, P.; Serrano, C.; Jones, R. L.; Attia, S.; D'Amato, G.; more...
    Oncology Research and Treatment (2021)

    Fulltext@MSK | Save
  • Exome-wide pan-cancer analysis of germline variants in 8,719 individuals finds little evidence of rare variant associations
    Journal Article

    Guan, Z.; Shen, R.; Begg, C. B.
    Human Heredity (2021)

    Fulltext@MSK | Save
  • Breast nodule in a male-to-female transgender (MFT) adolescent
    Meeting Abstract

    Essoh, S.; Kallakuri, A.; Heerdt, A.; Ten, S.
    Hormone Research in Paediatrics (2021)

    Fulltext@MSK | Save
  • Artificial intelligence in thyroid fine needle aspiration biopsies
    Review

    Kezlarian, B.; Lin, O.
    Acta Cytologica (2021)

    Fulltext@MSK | Save